DexCom, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
8.8
Very Bullish
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
DXCM
Consensus analyst target of $83.92 is 37% above current price.
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $83.92 (+36.8%)
24 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
DXCM
PFE
26.3×
Trailing P/E
19.4×
20.1×
Forward P/E
9.4×
19.3%
Profit Margin
12.4%
61.5%
Gross Margin
75.8%
35.6%
ROE
8.9%
15.0%
Revenue Growth
-1.2%
91.9%
Earnings Growth
—
—
Beta
0.39
—
Price / Book
—
$23.7B
Market Cap
$149.8B
$54 – $90
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →